Navigation Links
EMKinetics Announces Start of Pivotal Trial for the TranStim™ Transdermal Neuromodulation System
Date:10/14/2011

CAMPBELL, Calif., Oct. 14, 2011 /PRNewswire/ -- EMKinetics, Inc. announced today initiation of the TranStim™ Transdermal Neuromodulation System pivotal trial for patients suffering from urge incontinence and overactive bladder.  The 120-person trial will be conducted at 10-15 US centers.  Submission for CE mark and 510(k) clearance will follow the completion of the study.   EMKinetics' TranStim therapy builds on the body of evidence that posterior tibial nerve stimulation (PTNS) can generate a clinically significant improvement in patients suffering from urge incontinence and overactive bladder.  

"This appears to be the next evolutionary step for PTNS technology," said Marshall Stoller, MD, EMKinetics co-founder and professor and vice chair in the Department of Urology at the University of California, San Francisco. "We are confident that the TranStim System has the potential to safely and consistently provide transdermal PTNS therapy.  We believe this advancement will be well received by this desperate patient population and the physicians caring for them."  

The initiation of the pivotal trial follows the closing of EMKinetics' Series C financing of $8.0 million, led by a strategic investment from Allergan, Inc., a global multi-specialty healthcare company with a strong and growing urology portfolio.  Series B investor, Scientific Health Development, and four new institutional investors, Easton Capital, Oakwood Medical Investors, Legacy Life Sciences and Millennium Life Sciences Fund, filled out the round.

"Allergan, which is widely known for its specialty pharmaceuticals, has also become a significant participant in medical devices and is emerging as a leader in urologic therapies", said Daniel Burnett, MD, co-founder and director of EMKinetics. "Their financial support in an area they know so well is both gratifying and important to our company."

About EMKinetics, Inc.

The fourth venture-backed spin-out from incubator TheraNova, LLC, EMKinetics, Inc. is a clinical-stage medical technology company developing neuromodulation therapies based on its Transdermal Stimulation (TranStim™) technology. The EMKinetics technology focuses on neuromodulation for the treatment of overactive bladder and other maladies.  EMKinetics is headquartered in Campbell, CA.

EMKinetics, Inc. contact:
Hugh Sharkey, CEO
(650) 384-0008
www.EMKinetics.com


'/>"/>
SOURCE EMKinetics, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
2. EDAP Announces Launch of Clinical Study Combining HIFU and Chemotherapy for Localized Aggressive High Risk Prostate Cancer
3. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
4. ADVENTRX Announces Fast Track Designation Granted By the FDA For CoFactor For the Treatment of Metastatic Colorectal Cancer
5. DOV Pharmaceutical, Inc. Announces Successful Phase Ib Results for DOV 21,947
6. Phosphagenics Announces Positive Phase 1b Transdermal Insulin Clinical Trial Results
7. Xenomics Announces Implementation of its First Diagnostic Test for Acute Myeloid Leukemia Into Clinical Practice
8. Emisphere Technologies, Inc. Announces 2007 Second Quarter Financial Results
9. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
10. Genta Incorporated Announces Second Quarter 2007 Financial Results and Corporate Highlights
11. MicroDose Announces Positive Results From the QDose Inhaled Insulin Glucose Clamp Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/8/2017)... Fla. , June 8, 2017  Less than ... that hit more than 200,000 companies, including hospital networks, ... being heralded as one of the largest online extortion ... in the healthcare market, it is imperative that providers ... protect their data from this — and many other ...
(Date:6/7/2017)... June 7, 2017 Endo International plc (NASDAQ: ... 2017, the Hon. Joseph R. Goodwin , U.S. ... West Virginia , entered a case management ... Repair System Products Liability Litigation (the "MDL") that includes ... to provide expert disclosures on specific causation within one ...
(Date:6/5/2017)... 2017 The Cincinnati location ... Inc. (NYSE: DPLO), has been awarded a Top Workplaces ... Results are based on an employee survey administered by ... workplace improvement. The survey measures several aspects of workplace culture, ... ...
Breaking Medicine Technology:
(Date:6/26/2017)... ... 26, 2017 , ... New patients with missing teeth in Fitchburg, ... a referral. Dr. Cotey is a trusted dentist who has placed many dental implants ... Patients with missing teeth in Fitchburg, WI, are encouraged to find out if they ...
(Date:6/25/2017)... ... June 24, 2017 , ... Create a feel-good lyric music video in Final Cut Pro X ... the timeline and write in the lyrics to any song. ProLyric flies in the text ... of the text can be added modularly for optimal control. ProLyric makes editing any music ...
(Date:6/25/2017)... ... 25, 2017 , ... An increase in wetter weather in the Northern California ... with that; a humdinger of an allergy season. A relief from drought conditions is ... misery-causing grass and weed pollen. , “Our patients have been reporting the typical ...
(Date:6/25/2017)... ... ... With a heatwave currently bearing down on Northern California pushing temperatures to the maximum, many ... is easy with laser hair removal. , The process of summer waxing and constantly ... all you want to do is get out, dive in and cool off. There is ...
(Date:6/24/2017)... , ... June 24, 2017 , ... ... offering genetic testing for medications in select Florida and Texas doctors' offices and ... , This new application of genetic testing recognizes the role genes play in ...
Breaking Medicine News(10 mins):